ABIVAX Société Anonyme
AAVXF
$6.91
$1.0217.32%
| Weiss Ratings | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.11 | |||
| Price History | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 17.32% | |||
| 30-Day Total Return | 17.32% | |||
| 60-Day Total Return | -37.47% | |||
| 90-Day Total Return | -37.47% | |||
| Year to Date Total Return | -6.24% | |||
| 1-Year Total Return | -36.89% | |||
| 2-Year Total Return | 15.75% | |||
| 3-Year Total Return | -72.08% | |||
| 5-Year Total Return | -46.68% | |||
| 52-Week High % Change | -54.39% | |||
| 52-Week Low % Change | 17.32% | |||
| Price | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $15.15 | |||
| 52-Week Low Price | $5.89 | |||
| 52-Week Low Price (Date) | Jan 30, 2025 | |||
| 52-Week High Price (Date) | Apr 22, 2024 | |||
| Valuation | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 372.90M | |||
| Enterprise Value | 253.95M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.47 | |||
| Earnings Per Share Growth | 0.88% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 44.52 | |||
| Price/Book (Q) | 3.21 | |||
| Enterprise Value/Revenue (TTM) | 31.07 | |||
| Price | $6.91 | |||
| Enterprise Value/EBITDA (TTM) | -1.65 | |||
| Enterprise Value/EBIT | -1.65 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 62.92M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 33 1 53 83 09 63 | |||
| Address | -- | |||
| Website | www.abivax.com | |||
| Country | France | |||
| Year Founded | 2013 | |||
| Profitability | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,885.05% | |||
| Profit Margin | -1,965.41% | |||
| Management Effectiveness | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -46.81% | |||
| Return on Equity | -- | |||
| Income Statement | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | 9.77M | |||
| Revenue Per Share | $0.16 | |||
| Gross Profit (TTM) | 9.77M | |||
| EBITDA (TTM) | -183.76M | |||
| EBIT (TTM) | -184.09M | |||
| Net Income (TTM) | -191.94M | |||
| Net Income Avl. to Common (TTM) | -191.94M | |||
| Total Revenue Growth (Q YOY) | 198.49% | |||
| Earnings Growth (Q YOY) | -55.38% | |||
| EPS Diluted (TTM) | -3.47 | |||
| EPS Diluted Growth (Q YOY) | 11.33% | |||
| Balance Sheet | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 238.21M | |||
| Cash Per Share (Q) | $3.79 | |||
| Total Current Assets (Q) | 260.35M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 135.51M | |||
| Current Ratio (Q) | 3.039 | |||
| Book Value Per Share (Q) | $2.15 | |||
| Total Assets (Q) | 304.82M | |||
| Total Current Liabilities (Q) | 85.68M | |||
| Total Debt (Q) | 121.46M | |||
| Total Liabilities (Q) | 169.32M | |||
| Total Common Equity (Q) | 135.51M | |||
| Cash Flow | AAVXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 7.64M | |||
| Cash from Financing (TTM) | 280.16M | |||
| Net Change in Cash (TTM) | 116.89M | |||
| Levered Free Cash Flow (TTM) | -96.55M | |||
| Cash from Operations (TTM) | -167.34M | |||
